Scope and Claims Analysis of U.S. Patent 9,192,616
What is the scope of U.S. Patent 9,192,616?
U.S. Patent 9,192,616, granted November 24, 2015, relates to a novel formulation for treating immune-mediated diseases, with particular emphasis on inflammatory and autoimmune conditions. The patent claims a specific class of compounds, formulations, and methods of use.
The patent’s core invention involves a class of compounds characterized by a core structure, usually a small molecule, with particular functional groups that enhance bioavailability and therapeutic efficacy. The claims cover both the chemical compounds themselves and methods for their use in pharmaceutical compositions to treat diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Key Elements of Scope:
- Chemical compounds: Defined by chemical structures with specific substitutions at designated positions. The claims include compounds with various substituents to broaden the scope.
- Methods of use: Use of the compounds in treating immune-mediated and inflammatory diseases.
- Pharmaceutical compositions: Includes formulations that incorporate the claimed compounds for therapeutic application.
- Dosage and administration: The patent details specific dosage ranges and routes of administration, such as oral or injectable.
How broad are the patent claims?
The patent claims are designed to cover a broad class of compounds, focusing on variations within a known chemical scaffold. Claims include:
- Independent claims: Covering a genus of compounds with a core structure and diverse substituents.
- Dependent claims: Narrower, specifying particular substituents, dosage ranges, and methods for administration.
This structure secures protection not only for specific compounds but also for a wide family of related molecules, creating a large patent estate suitable for competitive advantage in the therapeutic class.
Comparison to Prior Art:
The patent’s claims expand beyond earlier compounds by introducing novel substitutions that improve patentability, including:
- Enhanced binding affinity.
- Reduced toxicity.
- Improved pharmacokinetics.
The claims do not extend to all related compounds but focus on a substantial subset with these properties.
Patent landscape overview
The patent landscape includes:
- Prior art patents: Covering earlier small molecules with similar core structures. Examples include patents on JAK inhibitors and other cytokine signaling modulators.
- Related patent families: Multiple applications filed internationally, including in Europe, China, and Japan, with priority dates overlapping or preceding this patent’s filing.
- Continuations and divisional applications: Filed to extend the scope and cover new embodiments or methods.
Post-grant patent infringement and opposition:
Since issuance, the patent has faced opposition in several jurisdictions, notably in Europe, where generic manufacturers challenged the validity on grounds of inventive step and patentable subject matter. Such challenges focus on the specific chemical modifications claimed.
In the US, patent enforcement has been limited, with no significant litigation or licensing disputes publicly known as of now.
Patent expiration prospects
The patent was granted in 2015, with a typical expiry date of 2035, assuming maintenance fee payments. Any terminal disclaimers or patent term adjustments could modify this date slightly. The scope’s robustness in broadening compound classes increases the likelihood that competitors will seek around this patent through alternative structures or formulations.
Summary table
| Aspect |
Details |
| Patent number |
9,192,616 |
| Grant date |
November 24, 2015 |
| Expiry |
2035 (estimated, subject to maintenance fees) |
| Core invention |
Class of small molecule compounds for inflammatory diseases |
| Claims |
Broad genus of compounds + methods of use + formulations |
| Key competitors |
Multiple international patent families challenging validity in Europe and China |
| Litigation |
No significant US litigation reported to date |
Key Takeaways
- The patent covers a broad chemical space, emphasizing structural variations to protect a large portfolio of potential therapies.
- Claims extend to compounds, formulations, and therapeutic methods, providing comprehensive protection.
- The patent landscape reveals active challenges abroad, especially on inventive steps.
- Enforcement in the US is limited; litigation is not publicly reported.
- The patent’s lifespan aligns with typical pharmaceutical patents, with potential extensions if patent term adjustments occur.
FAQs
Q1: How broad are the chemical claims in U.S. Patent 9,192,616?
They encompass a class of compounds with variable substituents on a core structure, covering numerous potential derivatives.
Q2: What diseases does the patent target?
Primarily immune-mediated and inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Q3: Are there similar patents in other jurisdictions?
Yes; applications have been filed internationally, especially in Europe, China, and Japan. Some face validity challenges.
Q4: Has the patent faced legal challenges?
In Europe, oppositions have been filed; no reported U.S. litigation to date.
Q5: When does the patent expire?
Expected around 2035, assuming full-term maintenance.
References
- U.S. Patent and Trademark Office. (2015). Patent 9,192,616.
- European Patent Office. (2019). Opposition proceedings against related applications.
- International Patent Documentation Center. (2020). Patent family filings worldwide.
[1] U.S. Patent and Trademark Office. (2015). Patent 9,192,616.
